Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening

Journal of Urology

Volumn 195, Issue 1, 2016, Pages 66-73

  Banerji, John S ^a   Wolff, Erika M ^a   Massman, John D ^a   Odem Davis, Katherine ^b   Porter, Christopher R ^a   Corman, John M ^a  

^a Sect of Urol and Ren Transplant   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

biopsy; early detection of cancer; government agencies; needle; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NONHUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE NEEDLE BIOPSY; RETROSPECTIVE STUDY; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES; ADVISORY COMMITTEE; BLOOD; EARLY CANCER DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; TREATMENT OUTCOME; VERY ELDERLY;

ADVISORY COMMITTEES; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 84983094881     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.07.099     Document Type: Article

References (29)

1. V.A. Moyer U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120
2. M.R. Cooperberg Implications of the new AUA guidelines on prostate cancer detection in the U.S Curr Urol Rep 15 2014 420
3. S.D. Kaffenberger, and D.F. Penson The politics of prostate cancer screening Urol Clin North Am 41 2014 249
4. L.B. Squiers, C.M. Bann, S.E. Dolina, and et al. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening Am J Prev Med 45 2013 182
5. S. Carlsson, A.J. Vickers, M. Roobol, and et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review J Clin Oncol 30 2012 2581
6. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, and et al. Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310
7. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, and et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125
8. P.F. Pinsky, A. Blacka, B.S. Kramer, and et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Clin Trials 7 2010 303
9. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
10. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027
11. J.A. Cohn, C.E. Wang, J.C. Lakeman, and et al. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation Urol Oncol 32 2014 41
12. B. Bhindi, M. Mamdani, G.S. Kulkarni, and et al. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates J Urol 193 2014 1519
13. R. Gulati, A. Tsodikov, R. Etzioni, and et al. Expected population impacts of discontinued prostate-specific antigen screening Cancer 120 2014 3519
14. M.R. Cooperberg, D.J. Pasta, E.P. Elkin, and et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938
15. A.V. D'Amico, R. Whittington, S.B. Malkowicz, and et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
16. M.J. Barry, F.J. Fowler Jr., M.P. O'Leary, and et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1992 1549
17. R Development Core Team (2008): R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. ISBN 3-900051-07-0. Available at http://www.R-project.org.
18. T.A. Stamey, N. Yang, A.R. Hay, and et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909
19. E.L. Paquette, L. Sun, L.R. Paquette, and et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing Urology 60 2002 756
20. J. Hugosson, S. Carlsson, G. Aus, and et al. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial Lancet Oncol 11 2010 725
21. S.B. Zeliadt, R.M. Hoffman, R. Etzioni, and et al. Influence of publication of US and European prostate cancer screening trials on PSA testing practices J Natl Cancer Inst 103 2011 520
22. A. Fenner Prostate cancer: USPSTF screening recommendation could lead to greater numbers of avoidable deaths Nat Rev Urol 11 2014 481
23. T.Y. Perez, M.R. Danzig, R.A. Ghandour, and et al. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices Urology 85 2015 85
24. A.B. Weiner, R. Etzioni, and S.E. Eggener Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance Eur Urol 66 2014 611
25. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and et al. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists Adv Anat Pathol 13 2006 57
26. A. Billis, M.S. Guimaraes, L.L. Freitas, and et al. The impact of the 2005 International Society of Urological Pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies J Urol 180 2008 548
27. K. Yamoah, C. Deville, N. Vapiwala, and et al. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men Urol Oncol 33 2015 70
28. F.A. Faisal, D. Sundi, and J.L. Cooper Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up Urology 84 2014 1434
29. A.M. Wolf, R.C. Wender, R.B. Etzioni, and et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010 CA Cancer J Clin 60 2010 70